Canntab Therapeutics Ltd (CSE:PILL) has unveiled a major milestone – as the firm along with partner Emblem Corp (CVE:EMC) have received Health Canada approval for research and development activities on oral sustained release formulations of Canntab’s cannabinoids product, sending shares higher.
PARIS, Ontario, May 14, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) (“Emblem” or the “Company”) and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of Health Canada approval for research and development activities on oral sustained release formulations of cannabinoids (the “Sustained Release Product” or the “Product”), which are the proprietary products conceived by Canntab representing significant progress in Emblem and Canntab’s partnership to develop long-acting cannabis formulations.
Canntab Therapeutics Ltd (CSE:PILL) shares started trading on the Canadian Securities Exchange on Friday, offering traders another way to play the cannabis industry on the most significant day of the year for marijuana enthusiasts.
Canntab Therapeutics Limited (CSE:PILL) (formerly Telferscot Resources Inc.) (“Canntab” or the “Company”) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the “CSE”) at the opening of the market on Friday, April 20, 2018 under the stock symbol “PILL”.
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) — Mission Ready Services Inc. (“Mission Ready” or the “Company”) (TSX-V:MRS) is pleased to announce that it has engaged Bristol Capital Ltd. (“Bristol”), a premier North-American investor relations and capital markets advisory firm.
CALGARY, April 5, 2018 /CNW/ – High Tide Ventures Inc. (“High Tide”) today announced that, since March 6, 2018 when the Alberta Gaming and Liquor Commission (“AGLC”) began accepting retail cannabis license applications, the company has applied for 25 licensed locations to date.
CALGARY, Alberta, March 26, 2018 (GLOBE NEWSWIRE) — Divestco Inc. (TSX-V:DVT) (“Divestco”) and Bird River Resources Inc. (CSE:BDR) (“Bird River”) today announced a cogeneration joint venture (the “Cogen”) which will convert natural gas to electricity via a boiler-turbine at an industry low cost of 1.4 cents per kilowatt hour (based on current natural gas spot prices). Regulatory approvals are in place for the Cogen system to feed up to 3 megawatts of electricity into the power grid. The Cogen has secured a reliable, long-term gas supply through a privately owned natural gas producer. Construction and implementation of the project is expected to take 4-5 months.
TORONTO, March 01, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”) (TSX-V:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, and Ehave, Inc. (“Ehave”) (OTCQB:EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, are pleased to announce that they have entered into a collaboration agreement to enable enhanced patient and clinical research data management for Revive’s research initiatives involving medical cannabis for the treatment of liver diseases.
SEATTLE, WA, March 07, 2018 (GLOBE NEWSWIRE) — CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering recent developments in the deployment of Ehave Inc.’s (OTCQB: EHVVF) Connect platform, an innovative bioinformatics tool that enables researchers, physicians, and patients to connect in a way that was never before possible. By bringing all of these parties together, everyone can work towards the common goal of improving patient outcomes on a highly personalized level.
VANCOUVER, March 5, 2018 /CNW/ – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB: EHVVF) (“Ehave”), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017. “Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially
